Advertisement
Advertisement
U.S. markets close in 55 minutes
Advertisement
Advertisement
Advertisement
Advertisement

Myriad Genetics, Inc. (MYGN)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
Visitors trend2W10W9M
24.65-0.59 (-2.34%)
As of 03:04PM EDT. Market open.
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Momentum

Momentum

Performance Outlook
Previous Close25.24
Open24.90
Bid24.83 x 900
Ask24.87 x 1400
Day's Range24.63 - 25.06
52 Week Range16.02 - 36.95
Volume136,357
Avg. Volume551,211
Market Cap1.988B
Beta (5Y Monthly)1.71
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for MYGN

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Myriad Genetics, Inc.
    Analyst Report: Myriad Genetics, Inc.Myriad Genetics is a molecular diagnostics company that provides testing services designed to assess an individual’s risk of developing a disease. The firm produces MyRisk, a 35-gene panel with the capability to identify the elevated risk of developing eight types of cancer. Other diagnostic products include BRACAnalysisCDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; Prequel, with is a noninvasive prenatal test; and Prolaris, which identifies prostate cancer patients that can pursue active surveillance. The firm offers biomarker discovery and companion diagnostic services to pharma and biotech companies
    Rating
    Fair Value
    Economic Moat
    14 days agoMorningstar
View more
Advertisement
Advertisement